• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Class 1 Device Recall Vial2Bag

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
 Class 1 Device Recall Vial2Bagsee related information
Date Initiated by FirmDecember 26, 2018
Date PostedJanuary 28, 2019
Recall Status1 Terminated 3 on July 20, 2022
Recall NumberZ-0768-2019
Recall Event ID 81877
510(K)NumberK072759 
Product Classification Set, i.V. Fluid transfer - Product Code LHI
ProductVial2BAG Transfer Device, REF 6070104, Single use only, Rx Only
Code Information UDI:  (01)07290108240047(17)190301(10)7885(90)36098093(91)6070104  Lot Numbers:  7885, 7889, 7889, 8300, 8391, 8646, 8788, 8950, 9038, 9039, 9166, 9167, 9669, 9682, 9982, A672, C063, C070 
FEI Number 3000223297
Recalling Firm/
Manufacturer
WEST PHARMA. SERVICES IL, LTD
4, Ha-Sheizaf
Ra'Anana Israel
Manufacturer Reason
for Recall
Adverse events have been reported with the use of oxytocin in conjunction with the 13mm Vial2Bag DC in pregnant women. Vial2Bag is recalled due to similarities with 13mm Vial2Bag DC.
FDA Determined
Cause 2
Device Design
ActionOn December 26, 2018, West Pharmaceutical Services, Inc. issued URGENT MEDICAL DEVICE CORRECTION and ACKNOWLEDGEMENT FORMS to their customers asking customers to avoid use of the drug oxytocin with the device. Actions to be taken by the Distributor: 1. Complete the required Acknowledgement and Receipt Form below and return (via email) to Kevin.Lentz@westpharma.com when complete (See attached form). 2. Prior to filling order / releasing shipments of any Vial2Bag DC 13mm products (which have been placed on hold per our request) to hospital customers, affix a copy of this Voluntary Field Corrective Action Notice to each carton of Vial2Bag DC 13mm products in your possession. 3. Notify and provide the letter to all accounts/customers where the Affected Product was distributed. 4. Because the assessment is ongoing, please be prepared for updates to the notification. Actions to be taken by the Customer/User: 1. As a temporary measure you should avoid use of the drug oxytocin with the Vial2Bag DC 13mm until further notice until a full assessment has been completed. 2. Affix the notice to each carton of Vial2Bag DC 13mm products in your possession. 3. In addition, provide the notice to personnel with responsibilities related to product selection and administration, and according to your internal procedures for notification of field corrective actions. 4. Please complete the Recall Acknowledgement and Receipt Form and return to Karen Crimi by email at cs@progressivemedinc.com when complete responses are available. On January 24, 2019, West Pharmaceutical Services, Inc. initiated a product removal and broadened their action by distributing AMENDED URGENT MEDICAL DEVICE RECALL notices to their customers to include removal of three (3) devices from the field. On February 1, 2019, West Pharmaceutical Services, Inc. expanded their recall to include an additional sixteen (16) lots and issued notices titled - 2nd AMENDED URGENT MEDICAL DEVICE RECALL not
Quantity in Commerce4.9 million units
DistributionUS Distributor in MO
Total Product Life CycleTPLC Device Report

1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls.
2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall.
3 For details about termination of a recall see Code of Federal Regulations (CFR) Title 21 §7.55.
510(K) Database510(K)s with Product Code = LHI
-
-